MolMed S.p.A. announced the suspension of the enrollment of new patients in the phase III clinical trial with Zalmoxis named...
The EU's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional...
MolMed S.p.A. announced that the European Commission has granted a Conditional Marketing Authorisation (CMA) for Zalmoxis, the first immunogene therapy,...